Novartis' new experimental actinium-based drug shows promise against prostate cancer. Early data on Sunday revealed ...
Novartis' experimental actinium-225 drug demonstrated significant anti-tumor activity in prostate cancer patients, including those previously treated with Pluvicto.
By Bhanvi Satija May 31 (Reuters) - Novartis said on Sunday that early data from its experimental actinium-based drug showed ...
Research found that the weight-loss medications may reduce the spread of several obesity-related cancers, including lung, ...
NHS advisors have again rejected pleas for potentially life-saving routine prostate cancer screening after concluding that ...
The UK National Screening Committee (UKNSC) has advised against routine prostate cancer screening for most men, concluding ...
Prostate cancer kills more than 10,000 men in England each year. For decades, urologists across the country have been ...
Genitourinary adverse events seen in both groups; similarly, very low rates of gastrointestinal adverse events seen with 2F SBRT, 5F SBRT.
Among men with high-risk localized prostate cancer, those receiving neoadjuvant apalutamide combination therapy had improved potency recovery by 12 months and reduced rates of positive margins ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results